title: Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori.
abstract: OBJECTIVE
  To study the eradication rate of Helicobacter pylori (Hp) in a group of type 2 diabetes and compared it with an age and sex matched non-diabetic group.
  
  
  METHODS
  40 diabetic patients (21 females, 19 males; 56+/-7 years) and 40 non-diabetic dyspeptic patients (20 females, 20 males; 54+/-9 years) were evaluated. Diabetic patients with dyspeptic complaints were referred for upper gastrointestinal endoscopies; 2 corpus and 2 antral gastric biopsy specimens were performed on each patient. Patients with positive Hp results on histopathological examination comprised the study group. Non-diabetic dyspeptic patients seen at the Gastroenterology Outpatient Clinic and with the same biopsy and treatment protocol formed the control group. A triple therapy with amoxycillin (1 g b.i.d), clarithromycin (500 mg b.i.d) and omeprazole (20 mg b.i.d.) was given to both groups for 10 days. Cure was defined as the absence of Hp infection assessed by corpus and antrum biopsies in control upper gastrointestinal endoscopies performed 6 weeks after completing the antimicrobial therapy.
  
  
  RESULTS
  The eradication rate was 50 % in the diabetic group versus 85 % in the non-diabetic control group (P<0.001).
  
  
  CONCLUSIONS
  Type 2 diabetic patients showed a significantly lower eradication rate than controls which may be due to changes in microvasculature of the stomach and to frequent antibiotic usage because of recurrent bacterial infections with the development of resistant strains.
authors.affiliation: Department of Endocrinology and Diabetes, Istanbul, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Sargýn
authors.forename: Oya
authors.initials: O
authors.lastname: Uygur-Bayramicli
authors.forename: Haluk
authors.initials: H
authors.lastname: Sargýn
authors.forename: Ekrem
authors.initials: E
authors.lastname: Orbay
authors.forename: Dilek
authors.initials: D
authors.lastname: Yavuzer
authors.forename: Ali
authors.initials: A
authors.lastname: Yayla
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D017291:Clarithromycin / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D011446:Prospective Studies
chemical_list: D000897:Anti-Ulcer Agents; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole